-
公开(公告)号:EP2296690B1
公开(公告)日:2016-11-30
申请号:EP09759330.5
申请日:2009-06-03
申请人: Amgen, Inc
发明人: BELOUSKI, Edward, John , ELLISON, Murielle, Marie , HAMBURGER, Agnes, Eva , HECHT, Randy, Ira , LI, Yue-Sheng , MICHAELS, Mark, Leo , SUN, Jeonghoon , XU, Jing
CPC分类号: C07K14/50 , A61K38/00 , A61K38/1825 , A61K2039/505 , C07K16/18 , C07K2319/30
摘要: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
-
公开(公告)号:EP2296690A2
公开(公告)日:2011-03-23
申请号:EP09759330.5
申请日:2009-06-03
申请人: Amgen, Inc
发明人: BELOUSKI, Edward, John , ELLISON, Murielle, Marie , HAMBURGER, Agnes, Eva , HECHT, Randy, Ira , LI, Yue-Sheng , MICHAELS, Mark, Leo , SUN, Jeonghoon , XU, Jing
CPC分类号: C07K14/50 , A61K38/00 , A61K38/1825 , A61K2039/505 , C07K16/18 , C07K2319/30
摘要: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
-
公开(公告)号:EP3027642B1
公开(公告)日:2020-08-19
申请号:EP14752711.3
申请日:2014-07-31
申请人: Amgen Inc.
发明人: XIONG, Yumei , ZHANG, Yi , SHENG, Jackie, Z. , HAMBURGER, Agnes, Eva , VENIANT-ELLISON, Murielle , SHIMAMOTO, Grant , MIN, Xiaoshan , WANG, Zhulun , TANG, Jie , KANNAN, Gunasekaran , MOCK, Marissa , WALKER, Kenneth
IPC分类号: C07K14/475 , A61P13/12 , A61P3/00
-
公开(公告)号:EP3027642A1
公开(公告)日:2016-06-08
申请号:EP14752711.3
申请日:2014-07-31
申请人: AMGEN, INC.
发明人: XIONG, Yumei , ZHANG, Yi , SHENG, Jackie, Z. , HAMBURGER, Agnes, Eva , VENIANT-ELLISON, Murielle , SHIMAMOTO, Grant , MIN, Xiaoshan , WANG, Zhulun , TANG, Jie , KANNAN, Gunasekaran , MOCK, Marissa , WALKER, Kenneth
IPC分类号: C07K14/495 , C12N15/62
摘要: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
-
-
-